Replies to post #720 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD, including the preclinical data and over 10 years of clinical data of ProSavin. The FDA also provided feedback on the design of the SUNRISE-PD phase 2 study of AXO-Lenti-PD and agreed that current manufacturing and quality control plans were adequate for the clinical program.

http://investors.axovant.com/news-releases/news-release-details/axovant-announces-third-fiscal-quarter-2018-financial-results

Good luck and GOD bless,